

CONFERENCE ON
**THE MANY
FACES OF OPEN
INNOVATION IN
SCIENCE**

**19 SEPTEMBER 2022
10AM - 3.30 PM**

REGISTRATION AND REFRESHMENTS FROM 9 AM

THE EVENT IS SPONSORED BY THE NOVO NORDISK FOUNDATION

novo
nordisk
fonden

ÓDIN



PRACTICAL INFORMATION

- **Venue** The Novo Nordisk Foundation
Tuborg Havnevej 19
2900 Hellerup
- **Registration** Everyone must register online
There are 150 available seats for the conference.
They are available on a first-come-first-served basis.

<https://events.au.dk/ois22>
- **Price** There are no participation fees.
- **Program** The program can be found on the next page.
Please note that participants can register from 9 AM while enjoying small refreshments.
- **Speakers** The last pages provides information on the 5 invited speakers - including title and abstract of the talks.
- **Stipends** 30 travel stipends (of a maximum of 900DKK) are available for Danish graduate students.
To apply for a stipend, please contact Ditte from the ODIN secretariat (dhe@au.dk) and state your name and affiliation. The stipends will be given to the students who must travel farthest on a first-come-first-served basis.
- **Support** The conference is sponsored and hosted by the Novo Nordisk Foundation

CONFERENCE PROGRAM

- **10.00** **Welcome**, Mikkel Skovborg, NNF
- **10.10** **Introduction**, Maria Theresa Norn, moderator
- **10.15** **Open Science, University-Industry Partnerships and Commercialization**
Aled Edwards, Toronto University
Structural Genomics Consortium
- **10.50** **Open Neuroscientific Discovery and Innovation in the Age of Acceleration**
Dylan Roskams-Edris, McGill University
The Tanenbaum Open Science Institute
- **11.25** **Short break**
- **11.45** **Into The Great Wide Open: Exploring New Uses of “no-IP” Collaborations in Denmark**
Marie Louise Conradsen, Aarhus University
Head of Open Science, ODIN
- **12.15** **Industry and Open Innovation in Science- A Boost and Needed Change in Pharma**
Niclas Nilsson, Lund University
Director of Innovation
- **12.45** **Lunch**
- **13.30** **The Role of Open Innovation in Science in Mission-driven Technology Development**
Alfred M. Sporman
The Novo Nordisk Foundation CO2 Research Center
Professor, Stanford
- **14.00** **Panel Q&A**
- **14.45** **Closing remarks**
Moderator Maria-Theresa Norn
- **15.00** **Networking** (30-minute closing session)

ALED EDWARDS

OPEN SCIENCE, UNIVERSITY-INDUSTRY PARTNERSHIPS AND COMMERCIALIZATION

For centuries, the main roles of universities in society have been to train and educate young people, and to contribute to the generation of new knowledge. However, over the past decades, there have been increasing calls for universities to play more active roles in translating this knowledge into products. This has led to the question as to how universities can accomplish this new mission without sacrificing their core mission. I will argue, drawing both on system-wide evidence and using specific examples, that the best way to deliver on the three university missions - training, knowledge generation and knowledge translation - is to work with industry under open science (never patent) principles.



ALED EDWARDS
CEO and founder of the SGC
Professor, Toronto University

Al leads the Structural Genomics Consortium (SGC), a public-private partnership in the biomedical research and pharmaceutical sector. The SGC generates research tools and knowledge to support basic science and early-stage drug discovery, and since 2004 has placed all its research output into the public domain without restriction, including without patents as a core principle. Al is a Professor and Temerty Nexus Chair of Health Innovation and Technology at the University Toronto.

DYLAN ROSKAMS-EDRIS

OPEN NEUROSCIENTIFIC DISCOVERY AND INNOVATION IN THE AGE OF ACCELERATION

The rate at which we generate information about the brain, and turn that information into novel discoveries and medical interventions, is continuously accelerating. Such acceleration presents an exciting opportunity to develop new knowledge and technologies, especially concerning the many neurological and mental health disorders for which there are no effective, long-term treatments.

In this talk, Dylan will address the exciting possibilities for accelerating discovery and innovation made possible by a more open neuroscience; the ethical, legal, regulatory, governance, and infrastructure challenges that must be overcome; and some of the solutions currently being developed and implemented around the world. Dylan will be drawing on the experience of The Neuro as the first open science biomedical research institute and hospital as well as other national and global open science initiatives.



DYLAN ROSKAMS-EDRIS **Open Science Alliance Officer** **The Tanenbaum Open Science Institute** **McGill University**

Dylan Roskams-Edris has a background in neuroscience, health ethics and intellectual property, health policy, and technology law. His research work focused on the impact of intellectual property law on research, innovation, and healthcare in the brain sciences.

As Open Science Alliance Officer for the Tanenbaum Open Science Institute (TOSI), Dylan interfaces with the national and global open science communities to promote the uptake of open science tools and practices in Canadian neuroscience research. Through his work, Dylan supports the adoption of Open Science through knowledge translation, resource sharing, and administering TOSI's Open Science Support and Partnership Framework.

MARIE LOUISE CONRADSEN

INTO THE GREAT WIDE OPEN: EXPLORING NEW USES OF “NO-IP” COLLABORATIONS IN DENMARK

At Aarhus University, we are currently embracing an open “no-IP” model for industry collaboration. We were inspired to do so by great international initiatives – but we quickly learned that we needed to adapt the concept to a Danish setting. In the presentation, I will present how the university uses openness as an agile “collaboration machine” and I will share our learnings from 1) open drug discovery platform ODIN and 2) our efforts to transfer the model to other research areas. For is OIS a “one-size-fits-all” for every field and industry? And how can open and closed IP tools supplement each other for more innovation?



MARIE LOUISE CONRADSEN
Head of Open Innovation in Science,
Aarhus University


Since 2016, Marie Louise has directed the university’s use of “open innovation in science” as a new model for IP-free industry collaboration. The model has been applied within several research areas incl. material sciences, food, drug discovery and carbon capture. Marie Louise holds a PhD from Copenhagen Business School and a MSc in Molecular Biology and The History of Science from Aarhus University.

NICLAS NILSSON

INDUSTRY AND OPEN INNOVATION IN SCIENCE - A BOOST AND NEEDED CHANGES IN PHARMA?

In the quest for new treatments, the pharmaceutical industry realizes the need for collaborations. It's becoming obvious that leveraging external competencies is a critical for success factor for innovation. The world is changing exponentially as not only novel technologies and new data is being developed and generated in an increasingly fast manner, but new business models, patients' needs, and healthcare providers' expectations create pressure on how we work.

Translating basic science to new treatments involves many different parties at different stages and enabling more effective collaborations requires new thinking and acting. Open Innovation is a concept of growing interest and sprung from a need to adjust to the change pressure the industry realizes that the smartest person doesn't work for you (anymore). What difference does this make and how can open innovation provide a boost that will allow both industry and academic parties to collaborate and mutually benefit when pursuing the translation of science to business and new treatments?



NICLAS NILSSON

Director of Innovation, Lund University

With a passion for interdisciplinary value creation, Niclas heads Lund University's Innovation unit tasked with creating impact in society based on employees, researchers, and students' ideas. With a strong track record LU innovation creates startups in medicine, life sciences, nanotech as well as other ways to improve society and human life.

Based on a PhD in medical sciences Niclas has about 20 years' experience from industrial R&D, particularly in pharmaceuticals and working with open innovation to improve collaborations between academia and industry. As head of Open Innovation at LEO Pharma Niclas established a novel and unique collaboration platform aiming to reduce hurdles between pharmaceutical R&D and external partners such as biotechs and academic research groups.

ALFRED M. SPORMANN

THE ROLE OF OPEN INNOVATION IN SCIENCE IN A MISSION DRIVEN CENTRE

New technologies for capturing CO₂ for conversion to climate-inert carbon or for use are key for timely mitigation of climate change.

Because of the sheer scale of CO₂ capture required as well as the speed at which new technologies have to be developed and deployed, technology transfers and ideation following traditional approaches are no longer possible.

New, faster and more effective platforms involving all stake holders need to be developed, which will be discussed in the presentation.



ALFRED M. SPORMANN
Executive Director, The Novo Nordisk Foundation CO₂ Research Center
Professor, Stanford

Alfred Spormann is Professor of Civil and Environmental Engineering as well Chemical Engineering at Stanford University, and the Executive Director of the Novo Nordisk Foundation CO₂ Research Center.

His primary research interests include the study of novel microbial metabolism with relevance to microbial CO₂ capture and conversion, bioenergy, and intestinal microbiology.

The Novo Nordisk Foundation CO₂ Research Center is a new, mission oriented Center based at Aarhus University, Denmark, with the purpose to develop novel science for CO₂ capture and CO₂ conversions for storage or utilization to replace fossil carbon and fossil fuel intensive processes with sustainable, CO₂ based technologies